Featured Research

from universities, journals, and other organizations

New Tool Helps Physicians Tailor Hormone Therapy For High-risk Prostate Cancer Patients

Date:
September 27, 2008
Source:
Fox Chase Cancer Center
Summary:
Using one of the largest databases of prostate cancer outcomes in the United States, Fox Chase Cancer Center researchers have developed a prediction tool that uses a patient's clinical information to estimate the benefit of adding androgen deprivation therapy of various durations to radiation therapy.

Using one of the largest databases of prostate cancer outcomes in the United States, Fox Chase Cancer Center researchers have developed a prediction tool that uses a patient's clinical information to estimate the benefit of adding androgen deprivation therapy of various durations to radiation therapy.

Such hormone therapy has been shown to help radiation kill prostate cancer cells and improve survival in men at a high risk of recurrence, but it is associated with significant side effects. Even when the cancer has been characterized as high-risk, the degree of benefit from the addition of androgen deprivation can be quite variable.

"Studies have generally lumped patients into three levels of risk, and physicians have recommended hormone therapy based on these studies," says Niraj H. Pahlajani, a resident in the radiation oncology department at Fox Chase Cancer Center in Philadelphia. "Our experience tells us that prostate patients can't be lumped together into broad categories and expected to respond the same way to treatment even when they fall into similar risk-categories. Fortunately, we've been able to generate a nuanced prediction tool that incorporates disease burden and individualizes treatment recommendations. We can enter each patient's clinical information and estimate the probability of the cancer coming back using different durations of hormone therapy to determine the best course."

Pahlajani says other similar tools exist to predict cancer treatment outcomes, but none is as personalized and none has yet been used to estimate the gains from different lengths of hormone therapy. The Fox Chase researchers used two key factors derived via biopsy to identify subtle differences among those at intermediate to high-risk of recurrence. The two factors were the percent of cancer-positive tissue identified and the percent of that positive tissue with a Gleason grade of four or five.

"With this information, we're able to personalize each man's treatment by quantifying the optimal duration of hormones based on his individual factors," Pahlajani says.

Pahlajani presented the study supporting the tool at the 50th annual meeting of the American Society for Therapeutic Radiology and Oncology.

In addition to Pahlajani, co-authors include Brian L. Egleston, Mark K. Buyyounouski, David Y.T. Chen, and Eric M. Horwitz of Fox Chase Cancer Center, and Alan Pollack of University of Miami. The authors report no disclosures. Funding for this study was provided by the National Cancer Institute and Varian Medical Systems.


Story Source:

The above story is based on materials provided by Fox Chase Cancer Center. Note: Materials may be edited for content and length.


Cite This Page:

Fox Chase Cancer Center. "New Tool Helps Physicians Tailor Hormone Therapy For High-risk Prostate Cancer Patients." ScienceDaily. ScienceDaily, 27 September 2008. <www.sciencedaily.com/releases/2008/09/080923140635.htm>.
Fox Chase Cancer Center. (2008, September 27). New Tool Helps Physicians Tailor Hormone Therapy For High-risk Prostate Cancer Patients. ScienceDaily. Retrieved April 24, 2014 from www.sciencedaily.com/releases/2008/09/080923140635.htm
Fox Chase Cancer Center. "New Tool Helps Physicians Tailor Hormone Therapy For High-risk Prostate Cancer Patients." ScienceDaily. www.sciencedaily.com/releases/2008/09/080923140635.htm (accessed April 24, 2014).

Share This



More Health & Medicine News

Thursday, April 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Deadly Fungus Killing Bats, Spreading in US

Deadly Fungus Killing Bats, Spreading in US

AP (Apr. 24, 2014) A disease that has killed more than six million cave-dwelling bats in the United States is on the move and wildlife biologists are worried. White Nose Syndrome, discovered in New York in 2006, has now spread to 25 states. (April 24) Video provided by AP
Powered by NewsLook.com
Companies Ramp Up Wellness to Lower Health Costs

Companies Ramp Up Wellness to Lower Health Costs

AP (Apr. 24, 2014) That little voice telling you to exercise, get in shape and get healthy is probably coming from your boss. More companies are beefing up wellness programs to try and cut down their health care costs. (April 24) Video provided by AP
Powered by NewsLook.com
Blood From World's Oldest Woman Suggests Life Limit

Blood From World's Oldest Woman Suggests Life Limit

Newsy (Apr. 24, 2014) Scientists say for the extremely elderly, their stem cells might reach a state of exhaustion. This could limit one's life span. Video provided by Newsy
Powered by NewsLook.com
FDA Wants To Ban Sales Of E-Cigarettes To Minors

FDA Wants To Ban Sales Of E-Cigarettes To Minors

Newsy (Apr. 24, 2014) The Food and Drug Administration wants to crack down on the use of e-cigarettes, banning the sale of the product to minors. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins